This review article presents select recent studies that form the basis for the development of esmethadone into a potential new drug. Esmethadone is a promising member of the pharmacological class of uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists that have shown efficacy for major depressive disorder (MDD) and other diseases and disorders, such as Alzheimer's dementia and pseudobulbar affect. The other drugs in the novel class of NMDAR antagonists with therapeutic uses that are discussed for comparative purposes in this review are esketamine, ketamine, dextromethorphan, and memantine. We present in silico, in vitro, in vivo, and clinical data for esmethadone and other uncompetitive NMDAR antagonists that may advance our understanding of the role of these receptors in neural plasticity in health and disease. The efficacy of NMDAR antagonists as rapid antidepressants may advance our understanding of the neurobiology of MDD and other neuropsychiatric diseases and disorders.

Esmethadone-HCl (REL-1017): a promising rapid antidepressant / M. Fava, S.M. Stahl, S. De Martin, A. Mattarei, E. Bettini, S. Comai, A. Alimonti, F. Bifari, L. Pani, F. Folli, C. Guidetti, A. Furlan, J. Sgrignani, P. Locatelli, A. Cavalli, C. O'Gorman, S. Traversa, C.E. Inturrisi, M. Pappagallo, P.L. Manfredi. - In: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE. - ISSN 0940-1334. - (2023), pp. 1-14. [Epub ahead of print] [10.1007/s00406-023-01571-4]

Esmethadone-HCl (REL-1017): a promising rapid antidepressant

F. Bifari
Investigation
;
F. Folli
Investigation
;
2023

Abstract

This review article presents select recent studies that form the basis for the development of esmethadone into a potential new drug. Esmethadone is a promising member of the pharmacological class of uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists that have shown efficacy for major depressive disorder (MDD) and other diseases and disorders, such as Alzheimer's dementia and pseudobulbar affect. The other drugs in the novel class of NMDAR antagonists with therapeutic uses that are discussed for comparative purposes in this review are esketamine, ketamine, dextromethorphan, and memantine. We present in silico, in vitro, in vivo, and clinical data for esmethadone and other uncompetitive NMDAR antagonists that may advance our understanding of the role of these receptors in neural plasticity in health and disease. The efficacy of NMDAR antagonists as rapid antidepressants may advance our understanding of the neurobiology of MDD and other neuropsychiatric diseases and disorders.
Esketamine; Esmethadone; Ketamine; Major depressive disorder; N-Methyl-D-aspartate receptor; REL-1017
Settore BIO/14 - Farmacologia
2023
8-mar-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
s00406-023-01571-4.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.42 MB
Formato Adobe PDF
1.42 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/969463
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact